Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Shell Companies

Financial Services
$10.90 +0.00%

+$0.00 today

Market cap
$264.62M
Beta
0.00
P/E (TTM)
36.7
EPS (TTM)
$0.29
52W Low $10.17High $10.63

Volume 0.00M

Average 0.11M

DMAA Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA

Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other non-current liabilities broadly unchanged from a year ago

Other non-current liabilities stood at $6.9M at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter.

Context

  • Other non-current liabilities amounted to 2.9% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.

What to watch

Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.9M+0.0% QoQ
Last fiscal yearDec 2025
$6.9M— YoY
Year agoMar 2025
$6.9M+0.0% since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
6.9M USD
Year-over-year change
—

Other Non-current Liabilities vs competitors

How DMAA compares with its peers on the latest reported figures

  • DMAA's Mar 2026 other non-current liabilities of $6.9M is the 7th highest of the 10 companies compared; the peer median is $11.71M.
  • Its year-over-year change of +0.0% is the 3rd highest of 6, against a peer median of +0.0%.
  • Other non-current liabilities amounts to 2.9% of total assets for DMAA, versus a peer median of 3.8%.
DMAA Competitors Peer median
Other Non-current Liabilities for DMAA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LOKVLive Oak Acquisition Corp. V Class A Ordinary SharesMar 2026$30.34M +119.8%—12.5%
ALFCenturion Acquisition Corp.Mar 2026$13.69M +0.0%—4.4%
TACHTitan Acquisition Corp.Mar 2026$13.14M +1.1558066231181312e+22%—4.6%
TACOUBerto Acquisition Corp. UnitMar 2026$11.71M ——3.8%
TACOBerto Acquisition Corp.Mar 2026$11.71M ——3.8%
OYSEOyster Enterprises II Acquisition CorpMar 2026$8.86M ——3.4%
DMAADrugs Made In America Acquisition Corp. Ordinary SharesMar 2026$6.9M +0.0%—2.9%
RTACRenatus Tactical Acquisition Corp I Class A Ordinary SharesMar 2026$1.73M -99.3%—0.7%
SIMASIM Acquisition Corp. IMar 2026$0 -100.0%—0.0%
MLACMountain Lake Acquisition Corp.Mar 2026$0 —-42.5%0.0%
Peer median (excluding DMAA) $11.71M+0.0%-42.5%3.8%

Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.